Active ingredientPralatrexateCat. No. P-P161-001CAS 146464-95-1Family · Pharmaceutical analytical standards
Pralatrexate
An antifolate designed to selectively enter tumour cells rich in the RFC-1 transporter; in 2009 it became the first drug approved in the United States for relapsed or refractory peripheral T-cell lymphoma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Research on this family of molecules began in the 1950s at SRI International; the drug later emerged from a collaboration with Memorial Sloan Kettering Cancer Center and the Southern Research Institute.
Go to the active ingredient →Active ingredientPralatrexateCat. No. P-P161-001CAS 146464-95-1
Isotopically labelledPralatrexate-d5Cat. No. P-P161-003
Impurity10-DeazaaminopterinCat. No. P-P161-004CAS 52454-37-2
Impurity2,4-Diaminopteridine-6-carboxylic acidCat. No. P-P161-005CAS 716-74-5
ImpurityPralatrexate Impurity 1Cat. No. P-P161-006CAS 2028268-08-6
ImpurityPralatrexate Impurity 2Cat. No. P-P161-007CAS 1445586-42-4
Impurity4-Hydroxy PralatrexateCat. No. P-P161-008CAS 1548618-61-6
ImpurityDes-Glu-PralatrexateCat. No. P-P161-009CAS 146464-93-9
Impuritygamma-Mono methyl ester PralatrexateCat. No. P-P161-010CAS 1548618-62-7
ImpurityPralatrexate EpimerCat. No. P-P161-011CAS 1451250-74-0
ImpurityPralatrexate Impurity 3Cat. No. P-P161-012
ImpurityPralatrexate Impurity 4Cat. No. P-P161-013
ImpurityPralatrexate Impurity 5Cat. No. P-P161-014
ImpurityPralatrexate Impurity 6Cat. No. P-P161-015CAS 374777-77-2
ImpurityR-PralatrexateCat. No. P-P161-016CAS 1320211-70-8
ImpurityS-PralatrexateCat. No. P-P161-017CAS 1320211-69-5No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.